JP2022527190A5 - - Google Patents

Info

Publication number
JP2022527190A5
JP2022527190A5 JP2021557925A JP2021557925A JP2022527190A5 JP 2022527190 A5 JP2022527190 A5 JP 2022527190A5 JP 2021557925 A JP2021557925 A JP 2021557925A JP 2021557925 A JP2021557925 A JP 2021557925A JP 2022527190 A5 JP2022527190 A5 JP 2022527190A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
pharmaceutically acceptable
hexenoyl
ghrh
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021557925A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022527190A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/025180 external-priority patent/WO2020205498A1/en
Publication of JP2022527190A publication Critical patent/JP2022527190A/ja
Publication of JP2022527190A5 publication Critical patent/JP2022527190A5/ja
Pending legal-status Critical Current

Links

JP2021557925A 2019-03-29 2020-03-27 肝疾患の治療で使用するためのｇｈｒｈまたはその類似物 Pending JP2022527190A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962826284P 2019-03-29 2019-03-29
US62/826,284 2019-03-29
US201962861187P 2019-06-13 2019-06-13
US62/861,187 2019-06-13
PCT/US2020/025180 WO2020205498A1 (en) 2019-03-29 2020-03-27 Ghrh or analogues thereof for use in treatment of hepatic disease

Publications (2)

Publication Number Publication Date
JP2022527190A JP2022527190A (ja) 2022-05-31
JP2022527190A5 true JP2022527190A5 (https=) 2023-04-05

Family

ID=72607731

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021557925A Pending JP2022527190A (ja) 2019-03-29 2020-03-27 肝疾患の治療で使用するためのｇｈｒｈまたはその類似物

Country Status (10)

Country Link
US (4) US10799562B1 (https=)
EP (1) EP3947426A4 (https=)
JP (1) JP2022527190A (https=)
KR (1) KR20210145226A (https=)
CN (1) CN113646327A (https=)
AU (1) AU2020253828A1 (https=)
CA (1) CA3133319A1 (https=)
IL (1) IL286703A (https=)
SG (1) SG11202110469PA (https=)
WO (1) WO2020205498A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202110469PA (en) 2019-03-29 2021-10-28 Massachusetts Gen Hospital Ghrh or analogues thereof for use in treatment of hepatic disease
CN115884783A (zh) * 2020-07-05 2023-03-31 瑟瑞技术公司 Ghrh类似物的低剂量药物组合物及其用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101678083A (zh) * 2007-04-04 2010-03-24 瑟瑞技术公司 Ghrh分子的药物制剂
US9163091B2 (en) * 2007-05-30 2015-10-20 Lpath, Inc. Compositions and methods for binding lysophosphatidic acid
US20150174207A1 (en) * 2013-12-24 2015-06-25 University Of Miami Methods for treating cancer with ghrh agonists
US20170105996A1 (en) * 2015-10-16 2017-04-20 Teva Pharmaceutical Industries, Ltd. Treatment of non-alcoholic fatty liver disease or non-alcoholic steatohepatitis with delayed-release 6-mercaptopurine
WO2017181277A1 (en) * 2016-04-19 2017-10-26 Griffon Pharmaceuticals Inc. Pegylated bioactive peptides and uses thereof
KR20200121308A (ko) * 2018-02-14 2020-10-23 루모스 파마, 인크. 비알코올성 지방간 질환 및 비알코올성 지방간염 치료용 조성물
SG11202110469PA (en) * 2019-03-29 2021-10-28 Massachusetts Gen Hospital Ghrh or analogues thereof for use in treatment of hepatic disease
WO2022093757A1 (en) * 2020-10-30 2022-05-05 The General Hospital Corporation Kits, reagents and methods for the assessment of liver diseases
US20220152012A1 (en) * 2020-11-16 2022-05-19 The Regents Of The University Of California Methods for regressing or reversing fibrosis and/or liver cirrhosis in a subject in need thereof using high-dose niacin, or a niacin analog thereof

Similar Documents

Publication Publication Date Title
JP6250588B2 (ja) Ｌ−オルニチンフェニル酢酸塩を用いる門脈圧亢進の治療及び肝機能の修復
Sahud et al. Effect of aspirin ingestion on ascorbic-acid levels in rheumatoid arthritis
JP2013082726A (ja) 鉄が病因に関与する肝臓疾患の処置
US20210322407A1 (en) Use of Trimetazidine in Preparation of Drugs for Preventing and Treating Liver Diseases
CA2440744C (en) Il-12 expression controlling agent
CA3049703A1 (en) New use of a long-acting mutant human fibroblast growth factor
CN109381472A (zh) 一种糖苷类化合物在制备用于治疗肝纤维化药物中的应用
JP2022527190A5 (https=)
TW202114671A (zh) 包含fxr促效劑之治療
CN111346081B (zh) 包含正戊酸、吲哚丙酸和正丁酸钠的药物组合物的新用途
Tang et al. Tetrahydroberberrubine exhibits preventive effect on obesity by activating PGC1α-mediated thermogenesis in white and brown adipose tissue
KR20220038339A (ko) Sglt 억제제, 예를 들어 sglt 1/2 억제제를 포함하는 치료
KR20150130352A (ko) 지방간 질환을 치료하는 방법
CN119424436B (zh) 化合物rociletinib通过抑制铁死亡在制备急性肝损伤的药物中的应用
US12257260B2 (en) Pharmaceutical use of anemoside B4 against acute gouty arthritis
US11278542B2 (en) Use of nicotinamide composition in preparation of drug for treating hand-foot skin reaction induced by sorafenib
CN112294787B (zh) 一种治疗肝癌的联合用药物
CN113244208A (zh) Hpa在制备治疗非酒精性脂肪性肝病药物中的应用
CN106806376A (zh) 对乙酰氨基酚和甘草酸或其盐或其衍生物的药物组合物
CN114366732B (zh) 泰妙菌素在制备用于治疗银屑病的药物中的应用
AU2009274022B2 (en) Compositions and methods for treating symptoms associated with menopause, hormonal variations and arthritis
Turdiyev et al. CHOLERETIC ACTIVITY OF RUTANA AT THERAPEUTIC APPLICATION IN RATS WITH HELIOTRIN HEPATITIS
RU2785582C2 (ru) Применение пегилированного рекомбинантного химерного фактора роста фибробластов-21 мыши или его фармацевтически приемлемой соли в составе лекарственных средств для лечения неалкогольного стеатогепатита
CN121243146A (zh) 3,5-二甲氧基-4-(2-氨基-3-(2-炔-丙硫烷)-丙酰基)-苯甲酸4-胍基-丁酰酯在医学中的新应用
CN117982489A (zh) 蟛蜞菊内酯防治非酒精性脂肪性肝病的应用